Member access

4-Traders Homepage  >  Shares  >  Deutsche Boerse AG  >  UCB SA    UNC   BE0003739530

UCB SA (UNC)

0
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Deutsche Boerse Ag
03/20/2015 03/23/2015 03/24/2015 03/25/2015 03/26/2015 Date
68.128(c) 69.247(c) 68.723(c) 69.084(c) 66.76(c) Last
0 0 0 0 87 Volume
+0.37% +1.64% -0.76% +0.53% -3.36% Change
More quotes
Financials (€)
Sales 2015 3 621 M
EBIT 2015 539 M
Net income 2015 311 M
Debt 2015 1 407 M
Yield 2015 1,73%
Sales 2016 3 928 M
EBIT 2016 694 M
Net income 2016 424 M
Debt 2016 1 215 M
Yield 2016 1,88%
PER 2015 41,10
PER 2016 29,21
EV / Sales 2015 4,02x
EV / Sales 2016 3,66x
Capitalization 13 152 M
More Financials
Company
UCB SA is a biopharmaceutical company that engages in the research, development and commercialization of innovative drugs in the fields of central nervous system and immunology disorders.It focuses on the discovery and development of innovative medicines and solutions to transform the lives of... 
Sector
Pharmaceuticals
Calendar
04/30Earnings Release
More about the company
Surperformance© ratings of UCB SA
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB SA
04:02a UCB : Convening notice to attend the general meeting of shareholders
03/25 UCB : Findings from UCB Pharma SA Yields New Findings on Toxicology (Identificat..
02/12 UCB : Patent Issued for Systems for Administering Medication
02/12 UCB : Patent Issued for Syringe Safety Assembly
01/29 UCB : announces US and EU regulatory filings for the investigational antiepilept..
01/12 UCB : Update of transparency notification UCB SA/NV
01/09 DERMIRA : and UCB announce start of Phase 3 program for CIMZIA (certolizumab peg..
01/07 UCB : Acquisition of own shares
More news
Sector news : Biopharmaceuticals
06:07a BAYER : New polymer for transparent sun protection -- Baycusan® C 2000 delivers ..
02:35a SHIRE : *repeat: ubs raises shire price target to 6600 pence - 'buy'
02:32a OTSUKA : Announces Change in Status of Representative Director (125KB)
More sector news : Biopharmaceuticals
Comments 
Advertisement
Chart UCB SA
Duration : Period :
UCB SA Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF